Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

Clotet, 2007, Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials, Lancet, 369, 1169, 10.1016/S0140-6736(07)60497-8 El-Sadr W, for the SMART Study Group. Inferior clinical outcomes with episodic CD4-guided antiretroviral therapy aimed at drug conservation (DC) in SMART study: consistency of finding in all patient subgroups. Toronto: 16th International AIDS Congress, 2006 (abstr WEAB0204). DeJesus E, LaMarca A, Sension M, Beltran C, Yeni P. The CONTEXT study: efficacy and safety of GW433908/r in PI-experienced subjects with virological failure (24 week results). Boston: 10th Conference on Retroviruses and Opportunistic Infections, 2003 (abstr 178). Johnson, 2005, Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures, AIDS, 19, 685, 10.1097/01.aids.0000166091.39317.99 Pollard RB, Thompson MA, Hicks CB, et al. Phase 3 comparison of lopinavir/ritonavir vs investigator-selected protease inhibitors in single PI-experienced, NNRTI-naive patients: 48-week results of study M98-888. Glasgow: Proceedings of the 7th International Congress on Drug Therapy in HIV Infection, 2004 (abstr PL3.2). Benson, 2002, Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients, J Infect Dis, 185, 599, 10.1086/339014 Hammer, 2006, Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel, JAMA, 296, 827, 10.1001/jama.296.7.827 Gazzard, 2006, British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006), HIV Med, 7, 487, 10.1111/j.1468-1293.2006.00424.x De Meyer S, Vangeneugden T, Lefebvre E, et al. Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3. Sitges: 15th International HIV Drug Resistance Workshop, 2006 (abstr 73). Johnson, 2006, Update of the drug resistance mutations in HIV-1: fall 2006, Top HIV Med, 14, 125 De Meyer S, De Paepe E, Vangeneugden T, et al. Effect of baseline and on-treatment mutations on the antiretroviral activity of darunavir/ritonavir (DRV/r) and lopinavir (LPV/r): results of a randomised, controlled, phase III study (TITAN). Sydney: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 2007 (abstr WEPEB038). Katlama, 2007, Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1, AIDS, 21, 395, 10.1097/QAD.0b013e328013d9d7 Haubrich, 2007, Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients, AIDS, 21, F11, 10.1097/QAD.0b013e3280b07b47 Lalezari, 2003, Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America, N Engl J Med, 348, 2175, 10.1056/NEJMoa035026 Nieto-Cisneros, 2003, Antiviral efficacy, metabolic changes and safety of atazanavir (ATV) versus lopinavir/ritonavir (LPV/r) in combination with 2 NRTIs in patients who have experienced virologic failure with prior PI-containing regimen(s): 24-week results from BMS A1424-043, Antivir Ther, 8, S212 Cozzi Lepri, 1998, The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection, AIDS, 12, 1639, 10.1097/00002030-199813000-00011